web analytics
15.8 C
Munich
Saturday, July 24, 2021

Rushnet Inc (OTCMKTS: RSHN) Powerful Runner as Acquisition of Sales Leader heliosDX; National Clinical Reference Laboratory Closes

Rushnet Inc (OTCMKTS: RSHN) is making a powerful run up the charts after announcing they closed the acquisition of heliosDX; a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. This acquisition brings significant value to RushNet, Inc and its shareholders. This acquisition turns Rushnet into a revenue powerhouse. RushNet, Inc and heliosDX have significant plans to reduce the current share structure and management has promised no RS. RSHN is quickly emerging as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. RSHN is looking to blaze a path along the likes of Tesoro or Enzolytics – Tesoro went to mulit dollars – a break over $0.0249 and RSHN is in a blue-sky breakout! 

heliosDX had annual revenues in 2019 of $2,639,454.58, 2020 of $4,294,435.82, and in 2021 through the 2nd Quarter of $2,827,582.50. heliosDX expects their current trends to hold and should meet their stretch goal of $6,000,000 for 2021. The company is profitable and has seen profits continue to grow right alongside the revenue growth. The company is also under a Binding Letter of Intent to acquire a privately held Laboratory slated to close late 3rd Quarter or early 4th Quarter. This acquisition will immediately bring heliosDX annual revenues to over $16,000,000 with a tremendous upside. helioDX is looking to acquire the building it occupies, which includes an empty space attached for future expansion. This first acquisition should yield annual revenues for heliosDX of $25,000,000 after a full 12 months of combined operations. We believe, as we continue to grow organically, along with acquisitions, we can reach and exceed $50,000,000 in annual revenue within two years. 

Rushnet Inc (OTCMKTS: RSHN) operating out of George has been reported on by Microcapdaily since October 27, 2018 when we reported: Rushnet Inc (OTCMKTS: RSHN) is an edible and beverage-based company with stand-alone products, including most enhanced with CBD. Currently, we have developed 12 Products that will take advantage of the organic grow, pristine mineral water enhancement and organic CBD.  RSHN is led by Frank Deangelo who used to be CEO of Applejam, Inc. which was one of the world’s largest restaurant franchises which he grew to having over $120,000,000 in sales with over 2500 employees before selling it. 

Newly acquired heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. Always staying ahead of the curve, by continually investing in our infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. We excel in patient and client care through physician designed panels that aid in testing compliance and reporting education. 

For the Inside Scoop on Rushnet Subscribe to Microcapdaily.com Right Now by entering your Email in the box belowc

RSHN

 

The combined operations vastly increase the heliosDX specimen capacity, sales representatives, and creates room for future growth in their infectious disease business, which is expected to outpace toxicology within 12 months. In a separate transaction, the company is seeking to purchase the building that the private company currently occupies, which includes an empty space attached for future expansion. This first acquisition should yield annual revenues for heliosDX of $25,000,000 after a full 12 months of combined operations. We believe, as we continue to grow organically, along with acquisitions, we can reach and exceed $50,000,000 in annual revenue within two years. 

Currently, heliosDX is in Alpharetta, GA which will remain the laboratory headquarters after the acquisition of the private laboratory. The company also just negotiated a new lease in Orange Park, Florida (Oakleaf Area) to open executive offices with an anticipated opening date of August 1, 2021. heliosDX is launching a National Sales Campaign utilizing Verb’s interactive technology and hired a Director of Virtual Sales to run this platform. This platform is anticipated to begin on August 1, 2021. We believe this platform will significantly increase the company’s ability to reach new clients at a fraction of the cost across the country. In late June 2021, heliosDX extended an offer to hire a Chief Operations Officer (COO), which has been accepted with a start date of August 2, 2021. Other executive positions are currently being explored and formal job postings will be made available on the company’s LinkedIn business page. 

We have a Monster Pick Coming. Subscribe Right Now!

Rushnet is making a powerful run up the charts after announcing they closed the acquisition of heliosDX; a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. This acquisition brings significant value to RushNet, Inc and its shareholders. This acquisition turns Rushnet into a revenue powerhouse. RushNet, Inc and heliosDX have significant plans to reduce the current share structure and management has promised no RS. RSHN is quickly emerging as an investors favorite and is currently among the most actively searched and talked about stocks in small caps. RSHN is looking to blaze a path along the likes of Tesoro or Enzolytics – Tesoro went to mulit dollars – a break over $0.0249 and RSHN is in a blue-sky breakout! heliosDX had annual revenues in 2019 of $2,639,454.58, 2020 of $4,294,435.82, and in 2021 through the 2nd Quarter of $2,827,582.50. heliosDX expects their current trends to hold and should meet their stretch goal of $6,000,000 for 2021. The company is profitable and has seen profits continue to grow right alongside the revenue growth. The company is also under a Binding Letter of Intent to acquire a privately held Laboratory slated to close late 3rd Quarter or early 4th Quarter. This acquisition will immediately bring heliosDX annual revenues to over $16,000,000 with a tremendous upside. helioDX is looking to acquire the building it occupies, which includes an empty space attached for future expansion. This first acquisition should yield annual revenues for heliosDX of $25,000,000 after a full 12 months of combined operations. We believe, as we continue to grow organically, along with acquisitions, we can reach and exceed $50,000,000 in annual revenue within two years. We will be updating on RSHN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RSHN.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in RSHN either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.